Discovery of new drugs that activate both blood sugar control and appetite regulation receptors

A novel oxyntomodulin-based dual agonist, OXM-7, shows potent hypoglycemic effects in mice.

• OXM-7 demonstrated both acute and long-acting hypoglycemic effects in ICR and db/db mice.
• Twice-daily administration of OXM-7 in diet-induced obesity mice led to significant weight loss.
• OXM-7 normalized lipid metabolism and improved glucose control in obese mice.
• In mice with diet-induced nonalcoholic steatohepatitis, OXM-7 significantly reversed liver fat accumulation.
• The treatment also reduced serum and liver lipid levels, indicating potential benefits for metabolic health.

Simplified